Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.

Kucey AS, Velenosi TJ, Tonial NC, Tieu A, RaoPeters AAE, Urquhart BL.

Pharmacol Res Perspect. 2019 Apr 26;7(3):e00475. doi: 10.1002/prp2.475. eCollection 2019 Jun.

2.

Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function.

Velenosi TJ, Thomson BKA, Tonial NC, RaoPeters AAE, Mio MA, Lajoie GA, Garg AX, House AA, Urquhart BL.

Sci Rep. 2019 May 2;9(1):6831. doi: 10.1038/s41598-019-42992-3.

3.

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development.

Takahashi S, Tanaka N, Fukami T, Xie C, Yagai T, Kim D, Velenosi TJ, Yan T, Krausz KW, Levi M, Gonzalez FJ.

Hepatol Commun. 2018 Oct 1;2(12):1567-1582. doi: 10.1002/hep4.1263. eCollection 2018 Dec.

4.

Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice.

Brocker CN, Patel DP, Velenosi TJ, Kim D, Yan T, Yue J, Li G, Krausz KW, Gonzalez FJ.

J Lipid Res. 2018 Nov;59(11):2140-2152. doi: 10.1194/jlr.M088419. Epub 2018 Aug 29.

PMID:
30158201
5.

Moderate Renal Impairment and Toxic Metabolites Produced by the Intestinal Microbiome: Dietary Implications.

Pignanelli M, Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Urquhart BL, Ruetz KN, Velenosi TJ, Spence JD.

J Ren Nutr. 2019 Jan;29(1):55-64. doi: 10.1053/j.jrn.2018.05.007. Epub 2018 Aug 9.

PMID:
30100156
6.

Mediterranean Diet Score: Associations with Metabolic Products of the Intestinal Microbiome, Carotid Plaque Burden, and Renal Function.

Pignanelli M, Just C, Bogiatzi C, Dinculescu V, Gloor GB, Allen-Vercoe E, Reid G, Urquhart BL, Ruetz KN, Velenosi TJ, Spence JD.

Nutrients. 2018 Jun 16;10(6). pii: E779. doi: 10.3390/nu10060779.

7.

Metabolic products of the intestinal microbiome and extremes of atherosclerosis.

Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Wong RG, Urquhart BL, Dinculescu V, Ruetz KN, Velenosi TJ, Pignanelli M, Spence JD.

Atherosclerosis. 2018 Jun;273:91-97. doi: 10.1016/j.atherosclerosis.2018.04.015. Epub 2018 Apr 17.

PMID:
29702430
8.

β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):604-611. doi: 10.2215/CJN.07470717. Epub 2018 Mar 8.

9.

Metabolomic Response of Skeletal Muscle to Aerobic Exercise Training in Insulin Resistant Type 1 Diabetic Rats.

Dotzert MS, Murray MR, McDonald MW, Olver TD, Velenosi TJ, Hennop A, Noble EG, Urquhart BL, Melling CW.

Sci Rep. 2016 May 20;6:26379. doi: 10.1038/srep26379.

10.

Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120.

Velenosi TJ, Hennop A, Feere DA, Tieu A, Kucey AS, Kyriacou P, McCuaig LE, Nevison SE, Kerr MA, Urquhart BL.

Sci Rep. 2016 Mar 2;6:22526. doi: 10.1038/srep22526.

11.

Enzymatic and non-enzymatic mechanisms of dimesna metabolism.

Cutler MJ, Velenosi TJ, Bodalia A, House AA, Urquhart BL, Freeman DJ.

Amino Acids. 2015 Mar;47(3):511-23. doi: 10.1007/s00726-014-1882-0. Epub 2014 Dec 10.

PMID:
25488427
12.

Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL.

Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. Epub 2014 Nov 21.

PMID:
25453994
13.

Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.

Feere DA, Velenosi TJ, Urquhart BL.

Br J Pharmacol. 2015 Jan;172(1):201-13. doi: 10.1111/bph.12932. Epub 2014 Nov 24.

14.

Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease.

Velenosi TJ, Feere DA, Sohi G, Hardy DB, Urquhart BL.

FASEB J. 2014 Dec;28(12):5388-97. doi: 10.1096/fj.14-258780. Epub 2014 Sep 10.

PMID:
25208844
15.

Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.

Velenosi TJ, Urquhart BL.

Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1131-43. doi: 10.1517/17425255.2014.931371. Epub 2014 Jun 24. Review.

PMID:
24961255
16.

CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to α1 adrenoceptor activation.

Gan XT, Taniai S, Zhao G, Huang CX, Velenosi TJ, Xue J, Urquhart BL, Karmazyn M.

Mol Cell Biochem. 2014 Sep;394(1-2):237-46. doi: 10.1007/s11010-014-2100-9. Epub 2014 Jun 4.

PMID:
24894822
17.

N-Acetylcysteine prevents congenital heart defects induced by pregestational diabetes.

Moazzen H, Lu X, Ma NL, Velenosi TJ, Urquhart BL, Wisse LJ, Gittenberger-de Groot AC, Feng Q.

Cardiovasc Diabetol. 2014 Feb 18;13:46. doi: 10.1186/1475-2840-13-46.

18.

Protein restoration in low-birth-weight rat offspring derived from maternal low-protein diet leads to elevated hepatic CYP3A and CYP2C11 activity in adulthood.

Sohi G, Barry EJ, Velenosi TJ, Urquhart BL, Hardy DB.

Drug Metab Dispos. 2014 Feb;42(2):221-8. doi: 10.1124/dmd.113.053538. Epub 2013 Nov 8.

PMID:
24212381
19.

Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.

Velenosi TJ, Fu AY, Luo S, Wang H, Urquhart BL.

Drug Metab Dispos. 2012 Aug;40(8):1508-14. doi: 10.1124/dmd.112.045245. Epub 2012 May 9.

PMID:
22573661
20.

In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.

Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.

J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.

PMID:
21505084

Supplemental Content

Loading ...
Support Center